Galapagos

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Pioneering For Patients

      We are Galapagos

      We are a biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life.

      Our Intent to Separate into Two Publicly Traded Entities

      On January 8, we announced a planned separation into two entities: Galapagos, which would continue to advance its global cell therapy leadership in addressing high unmet medical needs in oncology, and a newly to be formed company (“SpinCo”), which would focus on building a pipeline of innovative medicines through transformational transactions.

      Read moreOur pipeline

      Our Technology Platforms

      Small Molecules

      We are seeking partners to take over our small molecules’ assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic lupus erythematosus, dermatomyositis, and other potential auto-immune indications.

      Learn more

      Our Technology Platforms

      Cell Therapy

      • Scalable, decentralized, fast: stem-like, early memory cells near patients in median 7 days vein-to-vein
      • High-yielding discovery engine: multi-targeting, next-generation cell therapies
      • Diversify and grow: through partnerships and M&A
      Discover more

      LATEST PRESS RELEASES

      More

      STORIES OF PURPOSE

      Pioneering for Patients, with Patients!

      Patients and Carers

      At Galapagos, we put patients’ care and well-being first and foremost.

      Our goal is to improve patients’ quality of life through life-changing science and innovation.

      Discover our commitment to pioneering for patients, with patients!

      Discover our commitment